China Human Insulin Drugs Market Report 2022 to 2030

China Human Insulin Drugs Market Analysis

$ 3999

China Human Insulin Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. An increasing number of people with diabetes, increased exposure to key diabetes risk factors, rising market demand for human insulin analogues, technological advancements in the field of human insulin delivery devices, and favourable medical reimbursements are all expected to lead to an increase in the global market for human insulin. Some of the key players in this market are Sanofi (France), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Julphar (UAE), Ypsomed AG (Switzerland), BD (U.S.), etc.

ID: IN10CNPH303 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Riddhi Solanki

Buy Now

China Human Insulin Drugs Market Analysis Summary

China Human Insulin Drugs Market is valued at around $1766.2 Mn in 2022 and is projected to reach $2577.9 Mn by 2030, exhibiting a CAGR of 4.84% during the forecast period 2023-2030.

Blood sugar (glucose) levels are regulated by the hormone insulin, which is produced by the beta cells of the pancreatic islets of Langerhans. The body releases insulin when blood glucose levels increase, such as after a meal. When blood glucose levels fall, the liver begins to release glucose into the blood and insulin stops being secreted. The primary sites of action of insulin are adipose (fat), muscle, and liver tissues, which are essential for the metabolism and storage of nutrients. Like other protein hormones, insulin binds to particular receptors on target cells' outer membranes to trigger metabolic processes within those cells. Promoting the translocation of glucose transporters, which are molecules that mediate the uptake of glucose into the cell, is one of insulin's primary roles in these cells.

Type 1 diabetics and persons with severe type 2 diabetes must take insulin to keep their blood sugar levels within normal range. An increasing number of people with diabetes, increased exposure to key diabetes risk factors, rising market demand for human insulin analogues, technological advancements in the field of human insulin delivery devices, and favourable medical reimbursements are all expected to lead to an increase in the global market for human insulin. Some of the key players in this market are Sanofi (France), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Julphar (UAE), Ypsomed AG (Switzerland), BD (U.S.), Wockhardt Ltd. (India), B. Braun Melsungen AG (Switzerland), and Biodel Inc. (U.S.), Shanghai Fosun Pharmaceutical Co., Ltd (China), Tonghua Dongbao (China).

Market Dynamics

Market Growth Drivers

The market for human insulin is expected to grow as a result of factors including an increase in the prevalence of diabetes, increased exposure to the main risk factors for developing the disease, rising consumer demand for human insulin analogues, technological developments in the field of human insulin delivery devices, and favourable medical reimbursements. Some of the factors that are projected to fuel the rise of the insulin market include rising rates of obesity among the older population, an increase in the number of diabetic patients, public awareness of the advantages of insulin, and government initiatives to improve healthcare. Contrarily, a rise in the number of people with diabetes and a rise in the number of research and development projects involving insulin delivery systems will further encourage a number of opportunities that will aid the growth of the insulin industry.

Market Restraints

Strict regulatory standards for product clearance, rising insulin costs, unfavourable insurance policies, and increased competition among the current manufacturers will slow the market's growth rate.

Competitive Landscape

Key Players

Eli Lilly and Company
Novo Nordisk
Sanofi
Merck & Co., Inc.
AstraZeneca Plc
Pfizer Inc.
Bristol-Myers Squibb Company
Novartis AG
Johnson & Johnson
Takeda Pharmaceutical Company Limited

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

sexy Human Insulin Drugs Market Segmentation

By Disease Type

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Prediabetes

By Delivery Devices

Syringes
Pens
Pumps
Others

By Product Type

Intermediate Acting Insulin
Short Acting Insulin
Rapid Acting Insulin
Long-Acting Insulin

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.